Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
General Internal Medicine
•
Myeloproliferative Neoplasms
•
Hematology
How do you manage and/or prevent ruxolitinib withdrawal syndrome?
Answer from: Medical Oncologist at Community Practice
Generally, tapering over a week or two is the best way to prevent it. If immediate discontinuation is needed, can consider using steroids.
Sign in or Register to read more
14673
Related Questions
How do you evaluate a patient with MGUS and peripheral neuropathy?
How do you approach severe anemia and thrombocytopenia in an elderly patient whose bone marrow biopsy shows hypercellular marrow with mild dysplasia in erythroid and megakaryocytic lineage but normal cytogenetics and a negative NGS panel?
How does triple-negative status influence your management of ET?
How do you decide between using ropeginterferon alfa-2b and peginterferon alfa-2a in MPN?
How would you approach post-operative VTE prophylaxis for renal transplant in patients with a prior history of provoked VTE?
Would you change therapy for a CML patient in hematologic remission on imatinib found with positive qualitative BCR-ABL1 for the p230 protein?
What factors should be considered when deciding whether to omit radiation in pediatric/AYA patients receiving N+AVD, particularly regarding long-term outcomes and second malignancy risks?
For patients with intermediate or lower risk essential thrombocythemia with plt >1000 but no symptoms, do you favor aspirin only therapy or aspirin and cytoreduction?
How do you approach management for CCUS with severe cytopenias?
What experience have you had with familial clustering of polycythemia vera?